Episode 7 – Lessons learned part two: the value of biosimilars in rheumatology
01 września 2025
In Episode 7 of the Illuminoz podcast series, Bianca Stadler speaks with Professor Paul Emery – a leading rheumatology expert – about the journey of biosimilars in rheumatology and what it can teach us about their role in multiple sclerosis.
What challenges were faced during the introduction of biosimilars? What benefits have they brought to patients, clinicians, and healthcare systems? And how can these insights support better access and care in MS?
Tune in for a thoughtful discussion on how biosimilars have reshaped rheumatology—and what that could mean for neurology.
Informacje o podcaście:
“Illuminoz talks 2025” podcast series:
Episode 12 – PML: what is it, and why is it relevant in MS?
dr Tobias Bopp,
Episode 11 – Introducing biosimilar natalizumab
dr Heinz Wiendl,
Episode 10 – Patient conversations part three: the patient perspective
Ellen Tutton,
Episode 9 – Patient conversations part two: the nurse perspective
karolinamalicka,
Episode 8 – Patient conversations part one: the neurologist perspective
dr Agne Straukiene,
Episode 6 – Lessons learned part one: the value of biosimilars in oncology
prof. Kai Hübel,
Episode 5 – Biosimilars and MS: improving access to high-efficacy treatment
dr Barbara Kornek,
Episode 4 – Treatment paradigms in MS: right patient, right treatment, right time
dr Laura Airas,
Episode 3 – MS treatment landscape part two: potential role of biosimilars
dr David Paling,
Episode 2 – MS treatment landscape part one: unmet needs
dr Luisa Klotz,
Episode 1 – Biosimilars: what are they, and why might they be important for MS?
dr Wallace Brownlee,
